TRANSCELERATE BIOPHARMA INC: Form 990, tax year 2013
View the entire original 990 at ProPublica ↗
- Organization
- TRANSCELERATE BIOPHARMA INC (EIN 46-0886344)
- Tax period
- 2013-01-01 to 2013-12-31
- Filed
- 2014-11-10
- IRS object ID
- 201423149349300842
- Schema version
- 2013v3.0
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2014-11-10T10:18:20-06:00 | ReturnTs |
| Tax Period End | 2013-12-31 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 131639826 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | EISNERAMPER LLP | BusinessNameLine1 |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 101 WEST AVENUE PO BOX 458 | AddressLine1 |
| City | JENKINTOWN | City |
| State | PA | State |
| ZIP Code | 190460458 | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2013-01-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 460886344 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | TRANSCELERATE BIOPHARMA INC | BusinessNameLine1 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | TRAN | BusinessNameControlTxt |
| Phone | 6102707620 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 709 SWEDELAND ROAD NO UW2103 | AddressLine1 |
| City | KING OF PRUSSIA | City |
| State | PA | State |
| ZIP Code | 19406 | ZIPCode |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | DALVIR GILL PHD | PersonNm |
| Person Title | CEO | PersonTitleTxt |
| Phone | 6102707620 | PhoneNum |
| Signature | 2014-11-10 | SignatureDt |
| Discuss With Paid Preparer | Yes (1) | DiscussWithPaidPreparerInd |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | STEVEN GLUECK | PreparerPersonNm |
| PTIN | P00856557 | PTIN |
| Phone | 2158818800 | PhoneNum |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2013 | TaxYr |
| Build TS | 2015-11-30 17:44:51Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | DALVIR GILL PHD | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 709 SWEDELAND ROAD NO UW2103 | AddressLine1 |
| City | KING OF PRUSSIA | City |
| State | PA | State |
| ZIP Code | 19406 | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $13,643,765 | GrossReceiptsAmt |
| Group Return For Affiliates | 0 | GroupReturnForAffiliatesInd |
| Organization501c | Yes (X) | Organization501cInd |
| Website Address | WWW.TRANSCELERATEBIOPHARMAINC.COM | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 2012 | FormationYr |
| Legal Domicile State | PA | LegalDomicileStateCd |
| Activity Or Mission | TRANSCELERATE BIOPHARMA INC. IS A NON-PROFIT ORGANIZATION FOCUSED ON ADVANCING INNOVATION IN RESEARCH AND DEVELOPMENT (R&D) AND IDENTIFYING AND SOLVING COMMON R&D CHALLENGES WITH THE GOAL OF DELIVERING MORE HIGH QUALITY MEDICINES TO PATIENTS. | ActivityOrMissionDesc |
| Voting Members Governing Body | 17 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 16 | VotingMembersIndependentCnt |
| Total Employee | 2 | TotalEmployeeCnt |
| Total Volunteers | 0 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| Net Unrelated Bus Txbl Incm | $0 | NetUnrelatedBusTxblIncmAmt |
| PY Contributions Grants | $0 | PYContributionsGrantsAmt |
| CY Contributions Grants | $0 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $5,671,000 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $13,630,000 | CYProgramServiceRevenueAmt |
| PY Investment Income | $1,849 | PYInvestmentIncomeAmt |
| CY Investment Income | $13,765 | CYInvestmentIncomeAmt |
| PY Other Revenue | $0 | PYOtherRevenueAmt |
| CY Other Revenue | $0 | CYOtherRevenueAmt |
| PY Total Revenue | $5,672,849 | PYTotalRevenueAmt |
| CY Total Revenue | $13,643,765 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $0 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $0 | CYGrantsAndSimilarPaidAmt |
| PY Benefits Paid To Members | $0 | PYBenefitsPaidToMembersAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $0 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $1,109,529 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $0 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $0 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $16,752 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $5,494,217 | PYOtherExpensesAmt |
| CY Other Expenses | $5,713,774 | CYOtherExpensesAmt |
| PY Total Expenses | $5,494,217 | PYTotalExpensesAmt |
| CY Total Expenses | $6,823,303 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | $178,632 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | $6,820,462 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $5,857,436 | TotalAssetsBOYAmt |
| Total Assets EOY | $9,075,300 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $5,678,804 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $1,902,607 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $178,632 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $7,172,693 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | TRANSCELERATE BIOPHARMA INC. IS A NON-PROFIT ORGANIZATION FOCUSED ON ADVANCING INNOVATION IN RESEARCH AND DEVELOPMENT (R&D) AND IDENTIFYING AND SOLVING COMMON R&D CHALLENGES WITH THE GOAL OF DELIVERING MORE HIGH QUALITY MEDICINES TO PATIENTS. | MissionDesc |
| Significant New Program Srvc | Yes (1) | SignificantNewProgramSrvcInd |
| Significant Change | 0 | SignificantChangeInd |
| Expense | $3,943,936 | ExpenseAmt |
| Revenue | $13,630,000 | RevenueAmt |
| Desc | RISK BASED MONITORING - DEVELOP MODEL AND APPROACH FOR RISK BASED MONITORING OF CLINICAL TRIALS IN ORDER TO ENHANCE PATIENCE SAFETY AND ENSURE THE QUALITFY OF CLINCIAL TRIAL DATA.SHARED INVESTIGATOR PLATFORM - DEVELOP A SINGLE INTUITIVE INTERFACE FOR CLINICAL INVESTIGATORS USABLE ACROSS THE INDUSTRY. THE PLATFORM WILL REDUCE THE BURDEN ON CLINICAL TRIAL INVESTIGATORS AND SITES BY ENABLING A SINGLE SIGN-ON AND ACCESS TO MULTIPLE SPONSORS' SYSTEM THROUGH A SINGLE INTERFACE.SITE QUALIFICATION AND TRAINING- DEVELOPED A FRAMEWORK FOR MUTUAL RECOGNITION OF GCP TRAINING AND SITE QUALIFICATION CREDENTIALS IN ORDER TO REALIZE EFFICIENCIES AND ACCELERATE STUDY START-UP TIMELINES.CLINCIAL DATA STANDARDS - IN PARTNERSHIP WITH CDISC, FDA, AND THE CRTICAL PATH INSTITUE, DEVELOP INDUSTRY-WIDE DATA STANDARDS IN PRIORITY THERAPEUTIC AREAS TO SUPPORT THE EXCHANGE AND SUBMISSION OF CLINICAL RESEARCH AND META-DATA, IMPROVING PATIENT SAFETY AND OUTCOMES.COMPARATOR DRUGS - ESTABLISH RELIABLE, RAPID SOURCING OF QUALITY PRODUCTS FOR USE IN CLINICAL TRIALS THROUGH A COMPARATOR SUPPLY MODEL ENABLING ACCELERATED TRIAL TIMELINES AND ENHANCED PATIENT SAFETY.NEW INITIATIVES IN 2014:COMMON CLINICAL TRIAL PROTOCOL TEMPLATES - WORKING WITH OTHER INDUSTRY STAKEHOLDERS AND REGULATORS, TRANSCELERATE SEEKS TO DEVELOP A MODEL FORMAT FOR CLINICAL TRIAL PROTOCOLS AND PROTOCOL ENDPOINTS, IN ALIGNMENT WITH THE ONGOING TRANSCELERATE CLINICAL DATA STANDARDS PROJECT. THIS WILL SIMPLIFY STUDY PROTOCOLS, FACILITATE DATA INTERPRETATION AND ENABLE DOWN-STREAM AUTOMATION OF MANY CLINICAL PROCESSES, INCREASING PRODUCTIVITY AND REDUCING COSTS FOR INDUSTRY STAKEHOLDERS. SPECIAL POPULATIONS CLINICAL TRIAL NETWORKS (PEDIATRIC AND MINORITY) - TRANSCELERATE, WORKING CLOSELY WITH THE INVESTIGATOR COMMUNITY, WILL EXPLORE WAYS TO INCREASE THE NUMBER OF CLINICAL TRIALS AND NUMBER OF PATIENTS PARTICIPATING IN CLINCIAL TRIALS FOR DRUGS DEVELOPED TO TREAT CHILDREN, ADOLESCENTS AND MINORITY POPULATIONS WHICH WILL RESULT IN ACCELERATED DEVELOPMENT OF NEW DRUGS OR INDICATIONS AS WELL AS REDUCED CLINICAL TRIAL COSTS.INVESTIGATOR REGISTRY - TRANSCELERATE'S INVESTIGATOR REGISTRY WILL CREATE A SHARED REPOSITORY OF INVESTIGATOR CONTACT DETAILS ANDSITE-RELATED DATA. THIS INITIATIVE IS AIMED AT ACCELERATING THE IDENTIFICATION AND RECRUITMENT OF QUALIFIED INVESTIGATORS, WHICH WILL AVOID DUPLICATION OF STANDARD SITE AND LEAD TO THE CREATION OF A COMMON SOURCE FOR INVESTIGATOR DOCUMENTATION, AND THEREBY REDUCING COSTS AND TRIAL LENGTH.QUALITY MANAGEMENT SYSTEMS TRANSCELERATE IS EXPLORING WAYS TO IMPROVE QUALITY INDUSTRY-WIDE THROUGH PARTNERSHIPS WITH REGULATORY AGENCIES AND INDUSTRY STAKEHOLDERS TO ASSURE DATA INTEGRITY, MINIMIZE DELAYS IN CLINCIAL TRIALS, AND BRING DRUGS TO THE MARKET MORE QUICKLY.CLINICAL DATA TRANSPARENCY TRANSCELERATE IS DEVELOPING A POSITION ON THE BEST AND MOST EFFICIENT METHODS FOR REDACTING PRIVACY INFORMATION FOUND IN CLINICAL STUDY REPORTS. THE BENEFITS ARE TO MEET THE NEEDS OF INDUSTRY STAKEHOLDERS WHILE PRESERVING THE PRIVACY OF PATIENT, INVESTIGATORS, AND CLINICAL TRIAL STAFF. | Desc |
| Total Program Service Expenses | $3,943,936 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | 0 | DescribedInSection501c3Ind |
| Schedule B Required | 0 | ScheduleBRequiredInd |
| Political Campaign Acty | 0 | PoliticalCampaignActyInd |
| Subject To Proxy Tax | Yes (1) | SubjectToProxyTaxInd |
| Donor Advised Fund | 0 | DonorAdvisedFundInd |
| Conservation Easements | 0 | ConservationEasementsInd |
| Collections Of Art | 0 | CollectionsOfArtInd |
| Credit Counseling | 0 | CreditCounselingInd |
| Temp Or Permanent Endowments | 0 | TempOrPermanentEndowmentsInd |
| Report Land Building Equipment | Yes (1) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | 0 | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | 0 | ReportProgramRelatedInvstInd |
| Report Other Assets | 0 | ReportOtherAssetsInd |
| Report Other Liabilities | 0 | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | 0 | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | Yes (1) | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | 0 | ConsolidatedAuditFinclStmtInd |
| School Operating | 0 | SchoolOperatingInd |
| Foreign Office | 0 | ForeignOfficeInd |
| Foreign Activities | 0 | ForeignActivitiesInd |
| More Than5000 K To Org | 0 | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | 0 | MoreThan5000KToIndividualsInd |
| Professional Fundraising | 0 | ProfessionalFundraisingInd |
| Fundraising Activities | 0 | FundraisingActivitiesInd |
| Gaming Activities | 0 | GamingActivitiesInd |
| Operate Hospital | 0 | OperateHospitalInd |
| Grants To Organizations | 0 | GrantsToOrganizationsInd |
| Grants To Individuals | 0 | GrantsToIndividualsInd |
| Schedule J Required | Yes (1) | ScheduleJRequiredInd |
| Tax Exempt Bonds | 0 | TaxExemptBondsInd |
| Loan Outstanding | 0 | LoanOutstandingInd |
| Grant To Related Person | 0 | GrantToRelatedPersonInd |
| Business Rln With Org Mem | 0 | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | 0 | BusinessRlnWithFamMemInd |
| Business Rln With Officer Ent | 0 | BusinessRlnWithOfficerEntInd |
| Deductible Non Cash Contri | 0 | DeductibleNonCashContriInd |
| Deductible Art Contribution | 0 | DeductibleArtContributionInd |
| Terminate Operations | 0 | TerminateOperationsInd |
| Partial Liquidation | 0 | PartialLiquidationInd |
| Disregarded Entity | 0 | DisregardedEntityInd |
| Related Entity | 0 | RelatedEntityInd |
| Related Organization Ctrl Ent | 0 | RelatedOrganizationCtrlEntInd |
| Activities Conducted Prtshp | 0 | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (1) | ScheduleORequiredInd |
| IRP Document | 9 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Backup Wthld Compliance | Yes (1) | BackupWthldComplianceInd |
| Employee | 2 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (1) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | 0 | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | 0 | ForeignFinancialAccountInd |
| Prohibited Tax Shelter Trans | 0 | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | 0 | TaxablePartyNotificationInd |
| Nondeductible Contributions | 0 | NondeductibleContributionsInd |
| Indoor Tanning Services | 0 | IndoorTanningServicesInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 17 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 16 | IndependentVotingMemberCnt |
| Family Or Business Rln | 0 | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | 0 | DelegationOfMgmtDutiesInd |
| Change To Org Documents | Yes (1) | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | 0 | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | Yes (1) | MembersOrStockholdersInd |
| Election Of Board Members | Yes (1) | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | Yes (1) | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (1) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (1) | MinutesOfCommitteesInd |
| Officer Mailing Address | 0 | OfficerMailingAddressInd |
| Local Chapters | 0 | LocalChaptersInd |
| Form990 Provided To Gvrn Body | Yes (1) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (1) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | 0 | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | 0 | RegularMonitoringEnfrcInd |
| Whistleblower Policy | 0 | WhistleblowerPolicyInd |
| Document Retention Policy | 0 | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (1) | CompensationProcessCEOInd |
| Compensation Process Other | 0 | CompensationProcessOtherInd |
| Investment In Joint Venture | 0 | InvestmentInJointVentureInd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | ANTHONY GARGES FINANCE LEAD | BusinessNameLine1 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Phone | 6102707620 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 709 SWEDELAND ROAD | AddressLine1 |
| City | KING OF PRUSSIA | City |
| State | PA | State |
| ZIP Code | 19406 | ZIPCode |
Form990 Part VII Section A Form990PartVIISectionAGrp (19 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | OfficerOfficerInd |
|---|---|---|---|---|---|---|
| ANNALISA JENKINS | ||||||
| CHAIR OF BOARD OF DIRECTORS | 0.50 | Yes (X) | $0 | $0 | $0 | |
| STEVEN C GILMAN | ||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |
| JOHN M LEONARD | ||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |
| PABLO CAGNONI | ||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |
| BRIAN DANIELS | ||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |
| BRIGGS MORRISON | ||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |
| CORSEE SANDERS | ||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |
| ELIAS ZERHOUNI | ||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |
| GARRY NEIL | ||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |
| JAN LUNDBERG | ||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |
| JOHN HUBBARD | ||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |
| KLAUS DUGI | ||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |
| MARCO TAGLIETTI | ||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |
| PATRICK VALLANCE | ||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |
| PAUL STOFFELS | ||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |
| PETER CARBERRY | ||||||
| BOARD MEMBER | 0.50 | Yes (X) | $0 | $0 | $0 | |
| DALVIR GILL | ||||||
| CHIEF EXECUTIVE OFFICER | 40.00 | Yes (X) | $600,000 | $0 | $38,069 | Yes (X) |
| LYNN MARKS | ||||||
| CORPORATE SECRETARY | 0.50 | $0 | $0 | $0 | Yes (X) | |
| MARTIN FITCHET | ||||||
| TREASURER | 1.00 | $0 | $0 | $0 | Yes (X) | |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $600,000 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $0 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $38,069 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 1 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | 0 | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (1) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | 0 | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (4 entries)
| Address Line1ContractorAddress/USAddress/AddressLine1 | CityContractorAddress/USAddress/City | StateContractorAddress/USAddress/State | ZIP CodeContractorAddress/USAddress/ZIPCode | ServicesServicesDesc | CompensationCompensationAmt |
|---|---|---|---|---|---|
| ACCENTURE LLP | |||||
| 2005 MARKET ST ONE COMMERCE SQ 15TH | PHILADELPHIA | PA | 19103 | CONSULTING | $3,418,939 |
| SOA SOFTWARE INC | |||||
| 12100 WILSHIRE BLVD STE 1800 | LOS ANGELES | CA | 90025 | COMPUTER, SOFTWARE | $450,000 |
| PENTICO SOLUTIONS INC | |||||
| 385 BODINE RD | BERWYN | PA | 19312 | CONSULTING | $368,329 |
| KILPATRICK TOWNSEND & STOCKTON LLP | |||||
| 1114 AVENUE OF THE AMERICAS 21 | NEW YORK | NY | 10036 | LEGAL | $334,603 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 4 | CntrctRcvdGreaterThan100KCnt |
Program Service Revenue ProgramServiceRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | MEMBERSHIP DUES | Desc |
| Business | 900099 | BusinessCd |
| Total Revenue Column | $13,630,000 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $13,630,000 | RelatedOrExemptFuncIncomeAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Revenue | $13,630,000 | TotalProgramServiceRevenueAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $13,765 | TotalRevenueColumnAmt |
| Exclusion | $13,765 | ExclusionAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $13,643,765 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $13,630,000 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $13,765 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part IX | Yes (X) | InfoInScheduleOPartIXInd |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $983,069 | TotalAmt |
| Management And General | $983,069 | ManagementAndGeneralAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $81,360 | TotalAmt |
| Management And General | $81,360 | ManagementAndGeneralAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $18,007 | TotalAmt |
| Management And General | $18,007 | ManagementAndGeneralAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $27,093 | TotalAmt |
| Management And General | $27,093 | ManagementAndGeneralAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $569,795 | TotalAmt |
| Program Services | $359,462 | ProgramServicesAmt |
| Management And General | $210,333 | ManagementAndGeneralAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $104,590 | TotalAmt |
| Management And General | $104,590 | ManagementAndGeneralAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $4,660,849 | TotalAmt |
| Program Services | $3,512,093 | ProgramServicesAmt |
| Management And General | $1,148,756 | ManagementAndGeneralAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $46,631 | TotalAmt |
| Program Services | $5,133 | ProgramServicesAmt |
| Management And General | $41,498 | ManagementAndGeneralAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $40,674 | TotalAmt |
| Program Services | $17,549 | ProgramServicesAmt |
| Management And General | $23,125 | ManagementAndGeneralAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $30,000 | TotalAmt |
| Management And General | $30,000 | ManagementAndGeneralAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $100,255 | TotalAmt |
| Program Services | $5,949 | ProgramServicesAmt |
| Management And General | $94,306 | ManagementAndGeneralAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $56,817 | TotalAmt |
| Management And General | $56,817 | ManagementAndGeneralAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $52,472 | TotalAmt |
| Program Services | $43,750 | ProgramServicesAmt |
| Management And General | $8,722 | ManagementAndGeneralAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $34,939 | TotalAmt |
| Management And General | $34,939 | ManagementAndGeneralAmt |
Other Expenses OtherExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | MISCELLANEOUS | Desc |
| Total | $16,752 | TotalAmt |
| Fundraising | $16,752 | FundraisingAmt |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $6,823,303 | TotalAmt |
| Program Services | $3,943,936 | ProgramServicesAmt |
| Management And General | $2,862,615 | ManagementAndGeneralAmt |
| Fundraising | $16,752 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $394,218 | BOYAmt |
| EOY | $2,924,035 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $4,590,834 | BOYAmt |
| EOY | $4,505,325 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $847,800 | BOYAmt |
| EOY | $1,020,028 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $24,584 | BOYAmt |
| EOY | $40,326 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $638,058 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $52,472 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $585,586 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $5,857,436 | BOYAmt |
| EOY | $9,075,300 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $2,472,728 | BOYAmt |
| EOY | $706,431 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $3,206,076 | BOYAmt |
| EOY | $1,196,176 | EOYAmt |
Other Liabilities OtherLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $5,678,804 | BOYAmt |
| EOY | $1,902,607 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows SFAS117 | Yes (X) | OrganizationFollowsSFAS117Ind |
Unrestricted Net Assets UnrestrictedNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $178,632 | BOYAmt |
| EOY | $7,172,693 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $178,632 | BOYAmt |
| EOY | $7,172,693 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $5,857,436 | BOYAmt |
| EOY | $9,075,300 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Reconcilation Revenue Expnss | $6,820,462 | ReconcilationRevenueExpnssAmt |
| Donated Services And Use Fclts | $173,599 | DonatedServicesAndUseFcltsAmt |
| Other Changes In Net Assets | $0 | OtherChangesInNetAssetsAmt |
| Info In Schedule O Part XII | Yes (X) | InfoInScheduleOPartXIIInd |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | 0 | AccountantCompileOrReviewInd |
| FS Audited | Yes (1) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Separate Basis Fincl Stmt | Yes (X) | SeparateBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (1) | AuditCommitteeInd |
| Federal Grant Audit Required | 0 | FederalGrantAuditRequiredInd |
Schedule C IRS990ScheduleC
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantially All Dues Nonded | 0 | SubstantiallyAllDuesNondedInd |
| Only In House Lobbying | Yes (1) | OnlyInHouseLobbyingInd |
| Agree Carryover Prior Year | 0 | AgreeCarryoverPriorYearInd |
Schedule D IRS990ScheduleD
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $638,058 | OtherCostOrOtherBasisAmt |
| Depreciation | $52,472 | DepreciationAmt |
| Book Value | $585,586 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $585,586 | TotalBookValueLandBuildingsAmt |
| Footnote Text | Yes (X) | FootnoteTextInd |
| Total Rev Etc Audited Fincl Stmt | $23,831,850 | TotalRevEtcAuditedFinclStmtAmt |
| Donated Services And Use Fclts | $10,201,850 | DonatedServicesAndUseFcltsAmt |
| Revenue Not Reported | $10,201,850 | RevenueNotReportedAmt |
| Revenue Subtotal | $13,630,000 | RevenueSubtotalAmt |
| Other Revenues Not Included | $13,765 | OtherRevenuesNotIncludedAmt |
| Revenue Not Reported Fincl Stmt | $13,765 | RevenueNotReportedFinclStmtAmt |
| Total Revenue Per Form990 | $13,643,765 | TotalRevenuePerForm990Amt |
| Tot Expns Etc Audited Fincl Stmt | $16,851,554 | TotExpnsEtcAuditedFinclStmtAmt |
| Donated Services Use Fclts | $10,028,251 | DonatedServicesUseFcltsAmt |
| Expenses Not Reported | $10,028,251 | ExpensesNotReportedAmt |
| Expenses Subtotal | $6,823,303 | ExpensesSubtotalAmt |
| Expenses Not Rpt Fincl Stmt | $0 | ExpensesNotRptFinclStmtAmt |
| Total Expenses Per Form990 | $6,823,303 | TotalExpensesPerForm990Amt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART XI, LINE 4B - OTHER ADJUSTMENTS: | FormAndLineReferenceDesc |
| Explanation | INVESTMENT INCOME 13,765. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantiation Required | Yes (1) | SubstantiationRequiredInd |
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | 0 | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | 0 | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | 0 | EquityBasedCompArrngmInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | DALVIR GILL | PersonNm |
| Title | CHIEF EXECUTIVE OFFICER | TitleTxt |
| Base Compensation Filing Org | $500,000 | BaseCompensationFilingOrgAmt |
| Compensation Based On Rltd Orgs | $0 | CompensationBasedOnRltdOrgsAmt |
| Bonus Filing Organization | $100,000 | BonusFilingOrganizationAmount |
| Bonus Related Organizations | $0 | BonusRelatedOrganizationsAmt |
| Other Compensation Filing Org | $0 | OtherCompensationFilingOrgAmt |
| Other Compensation Rltd Orgs | $0 | OtherCompensationRltdOrgsAmt |
| Deferred Compensation Flng Org | $0 | DeferredCompensationFlngOrgAmt |
| Deferred Comp Rltd Orgs | $0 | DeferredCompRltdOrgsAmt |
| Nontaxable Benefits Filing Org | $38,069 | NontaxableBenefitsFilingOrgAmt |
| Nontaxable Benefits Rltd Orgs | $0 | NontaxableBenefitsRltdOrgsAmt |
| Total Compensation Filing Org | $638,069 | TotalCompensationFilingOrgAmt |
| Total Compensation Rltd Orgs | $0 | TotalCompensationRltdOrgsAmt |
| Comp Report Prior990 Filing Org | $0 | CompReportPrior990FilingOrgAmt |
| Comp Report Prior990 Rltd Orgs | $0 | CompReportPrior990RltdOrgsAmt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 3 | FormAndLineReferenceDesc |
| Explanation | THE BOARD APPROVES THE COMPENSATION AND BONUS OF THE CEO. | ExplanationTxt |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (12 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PART III, LINE 2 | UPDATE: TRANSCELERATE BIOPHARMA INC LAUNCHED FIVE FURTHER INITIATIVES WHICH INCLUDE THE CREATION OF A COMMON CLINICAL TRIAL PROTOCOL TEMPLATES, A PROJECT TO IMPROVE THE PARTICIPATION OF PEDIATRIC AND DIVERSE PATIENT POPULATIONS, THE DEVELOPMENT OF A GLOBAL INVESTIGATOR REGISTRY, A PROJECT FOCUSED ON QUALITY INDUSTRY WIDE, AND THE DEVELOPMENT OF THE MOST EFFICIENT METHOD OF REDACTING PRIVACY INFORMATION IN CLINICAL STUDY REPORTS. |
| FORM 990, PART VI, SECTION A, LINE 4 | SECTION 2.01(A)(I) OF THE BYLAWS ORIGINALLY PROVIDED THAT: THE INITIAL TIER 1 MEMBERS, DEFINED AS THOSE MEMBERS WHOSE MEMBERSHIP HAS BEEN ACCEPTED BY THE BOARD OF DIRECTORS AND WHICH HAVE PAID THE INITIAL MEMBERSHIP DUES WITHIN SIXTY (60) DAYS OF INCORPORATION OF THE CORPORATION, SHALL BE THE CHARTER MEMBERS OF THE CORPORATION. THE BOARD OF DIRECTORS VOTED TO AMEND THE BYLAWS TO PROVIDE THE INITIAL TIER 1 MEMBERS, DEFINED AS THOSE MEMBERS WHOSE MEMBERSHIP HAS BEEN ACCEPTED BY THE BOARD OF DIRECTORS AND WHICH HAVE PAID THE INITIAL MEMBERSHIP DUES BY NO LATER THAN DECEMBER 31, 2012, SHALL BE THE CHARTER MEMBERS OF THE CORPORATION. 2. SECTION 2.01(A)(II) OF THE BYLAWS ORIGINALLY PROVIDED THAT: TO BE ELIGIBLE FOR TIER II MEMBERSHIP, A FIRM OR CORPORATION MUST BE A PHARMACEUTICAL OR BIOTECHNOLOGY COMPANY WITH AN ANNUAL BUDGET FOR RESEARCH AND DEVELOPMENT THAT IS LESS THAN $2.5 BILLION BUT MORE THAN $500 MILLION. THE BOARDED OF DIRECTORS VOTED TO AMEND THE BYLAWS TO PROVIDE: TO BE ELIGIBLE FOR TIER II MEMBERSHIP, A FIRM OR CORPORATION MUST BE A PHARMACEUTICAL OR BIOTECHNOLOGY COMPANY WITH AN ANNUAL BUDGET FOR RESEARCH AND DEVELOPMENT THAT IS LESS THAN $2.5 BILLION BUT MORE THAN $100 MILLION. 3. SECTION 2.01(A)(III) OF THE BYLAWS ORIGINALLY PROVIDED THAT: TO BE ELIGIBLE FOR ASSOCIATE MEMBERSHIP, A FIRM OR CORPORATION MUST BE A PHARMACEUTICAL OR BIOTECHNOLOGY COMPANY WITH AN ANNUAL BUDGET FOR RESEARCH AND DEVELOPMENT THAT IS LESS THAN $500 MILLION OR BE AN EXTERNAL PARTNER OF PHARMACEUTICAL COMPANIES IN CLINICAL TRIALS. THE BOARDED OF DIRECTORS VOTED TO AMEND THE BYLAWS TO PROVIDE: TO BE ELIGIBLE FOR ASSOCIATE MEMBERSHIP, A FIRM OR CORPORATION MUST BE A PHARMACEUTICAL OR BIOTECHNOLOGY COMPANY WITH AN ANNUAL BUDGET FOR RESEARCH AND DEVELOPMENT THAT IS LESS THAN $100 MILLION OR BE AN EXTERNAL PARTNER OF PHARMACEUTICAL COMPANIES IN CLINICAL TRIALS. 4. SECTION 3.02 OF THE BYLAWS ORIGINALLY PROVIDED THAT: THE INITIAL BOARD OF DIRECTORS SHALL BE COMPRISED OF UP TO SEVENTEEN (17) MEMBERS; PROVIDED THAT: (I) A MINIMUM OF TEN (10) SEATS SHALL BE FILLED BY DIRECTORS WHO ARE REPRESENTATIVES OF THE TIER I MEMBERS WHO ARE CHARTER MEMBERS (AS DESIGNATED AS SUCH BY THE BOARD OF DIRECTORS OF THE CORPORATION IN ITS SOLE DISCRETION) (CHARTER MEMBER DIRECTORS) AND, IF SUCH NUMBER IS INCREASED IN THE FUTURE, THE REMAINDER OF SUCH SEATS RESERVED MAY BE FILLED BY TIER I MEMBERS THAT ARE NOT CHARTER MEMBERS (TIER I DIRECTORS); (II) AT LEAST FIVE (5) SEATS SHALL BE FILLED BY DIRECTORS WHO ARE REPRESENTATIVES OF THE TIER II MEMBERS (TIER II DIRECTORS) . . . . THE BOARDED OF DIRECTORS VOTED TO AMEND THE BYLAWS TO PROVIDE: THE BOARD OF DIRECTORS SHALL BE COMPRISED OF UP TO TWENTY (20) MEMBERS; PROVIDED THAT: (I) A MINIMUM OF TWELVE (12) SEATS SHALL BE FILLED BY DIRECTORS WHO ARE REPRESENTATIVES OF THE TIER I MEMBERS WHO ARE CHARTER MEMBERS (AS DESIGNATED AS SUCH BY THE BOARD OF DIRECTORS OF THE CORPORATION IN ITS SOLE DISCRETION) (CHARTER MEMBER DIRECTORS) AND, IF SUCH NUMBER IS INCREASED IN THE FUTURE, THE REMAINDER OF SUCH SEATS RESERVED MAY BE FILLED BY TIER I MEMBERS THAT ARE NOT CHARTER MEMBERS (TIER I DIRECTORS); (II) AT LEAST SIX (6) SEATS SHALL BE FILLED BY DIRECTORS WHO ARE REPRESENTATIVES OF THE TIER II MEMBERS (TIER II DIRECTORS) . . . . |
| FORM 990, PART VI, SECTION A, LINE 6 | THE MEMBERS OF THE CORPORATION CONSIST OF SUCH FIRMS AND CORPORATIONS THAT ARE APPROVED FOR MEMBERSHIP FROM TIME TO TIME BY THE BOARD OF DIRECTORS OR ITS DESIGNEES IN ACCORDANCE WITH THE POLICIES AND PROCEDURES OF THE CORPORATION. THE CORPORATION HAS THE FOLLOWING CATAGORIES OF MEMBERS: A. TIER I MEMBERS - TO BE ELIGIBLE FOR TIER I MEMBERSHIP, A FIRM OR CORPORATION MUST BE A PHARMACEUTICAL OR BIOTECHNOLOGY COMPANY WITH AN ANNUAL BUDGET FOR RESEARCH AND DEVELOPMENT IN EXCESS OF $2.5 BILLION. ELIGIBILITY FOR TIER I MEMBERSHIP IS ESTABLISHED BASED UPON A COMPANY'S PUBLICALLY AVAILABLE RESEARCH AND DEVELOPMENT EXPENDITURES OVER THE THREE (3) YEAR PERIOD PRECEDING THE DATE THE COMPANY APPLIES TO JOIN THE CORPORATION. THE INITIAL TIER 1 MEMBER ARE FURTHER DEFINED AS THE "CHARTER MEMBERS. B. TIER II MEMBERS - TO BE ELIGIBLE FOR TIER II MEMBERSHIP, A FIRM OR CORPORATION MUST BE A PHARMACEUTICAL OR BIOTECHNOLOGY COMPANY WITH AN ANNUAL BUDGET FOR RESEARCH AND DEVELOPMENT THAT IS LESS THAN $2.5 BILLION BUT MORE THAN $100 MILLION. ELIGIBILITY FOR TIER II MEMBERSHIP WILL BE ESTABLISHED BASED UPON A COMPANY'S PUBLICALLY AVAILABLE RESEARCH AND DEVELOPMENT EXPENDITURES OVER THE THREE (3) YEAR PERIOD PRECEDING THE DATE THE COMPANY APPLIES TO JOIN THE CORPORATION. C.ASSOCIATE MEMBERS - TO BE ELIGIBLE FOR ASSOCIATE MEMBERSHIP, A FIRM OR CORPORATION MUST BE A PHARMACEUTICAL OR BIOTECHNOLOGY COMPANY WITH AN ANNUAL BUDGET FOR RESEARCH AND DEVELOPMENT THAT IS LESS THAN $100 MILLION OR BE AN EXTERNAL PARTNER OF PHARMACEUTICAL COMPANIES IN CLINICAL TRIALS. |
| FORM 990, PART VI, SECTION A, LINE 7A | THE CORPORATIONS BY-LAWS STATE THAT DIRECTORS SHALL BE ELECTED OR APPOINTED, AS APPLICABLE, ANNUALLY AT THE ANNUAL MEETING OF MEMBERS AND SHALL SERVE UNTIL THE FOLLOWING ANNUAL MEETING OF MEMBERS AND UNTIL THEIR SUCCESSORS ARE ELECTED OR APPOINTED, AS APPLICABLE, AND QUALIFIED. EACH CHARTER MEMBER SHALL HAVE THE RIGHT TO APPOINT A REPRESENTATIVE OF THE CHARTER MEMBER TO SERVE AS A CHARTER MEMBER DIRECTOR. TIER I DIRECTORS SHALL BE ELECTED BY A PLURALITY VOTE OF THE TIER I MEMBERS, WHICH INCLUDE THE CHARTER MEMBERS. TIER II DIRECTORS SHALL BE ELECTED BY A PLURALITY VOTE OF THE TIER II MEMBERS. THE ASSOCIATE MEMBER DIRECTOR SHALL BE ELECTED BY A PLURALITY VOTE OF THE ASSOCIATE MEMBERS. THE CEO DIRECTOR SHALL SERVE EX-OFFICIO, FOR SO LONG AS HE OR SHE SHALL HOLD THE OFFICE OF CHIEF EXECUTIVE OFFICER. |
| FORM 990, PART VI, SECTION A, LINE 7B | EACH TIER I MEMBER SHALL BE ENTITLED TO THREE (3) VOTES AT EVERY MEETING OF MEMBERS ON MATTERS WHICH TIER 1 MEMBERS ARE ENTITLED TO VOTE. EACH TIER II MEMBER SHALL BE ENTITLED TO ONE (1) VOTE AT EVERY MEETING OF MEMBERS ON MATTERS WHICH TIER II MEMBERS ARE ENTITLED TO VOTE. ASSOCIATE MEMBERS SHALL BE ENTITLED TO NOTICE OF AND TO ATTEND MEETINGS OF THE MEMBERS BUT SHALL NOT BE ENTITLED TO VOTE AT SUCH MEETINGS, PROVIDED HOWEVER, ASSOCIATE MEMBERS SHALL HAVE THE RIGHT TO CAST ONE (1) VOTE EACH WITH RESPECT TO THE ELECTION OF THE NOMINEE TO FILL THE ASSOCIATE MEMBER BOARD POSITION. NOTWITHSTANDING THE ABOVE, IN ORDER TO BE ELIGIBLE TO VOTE, A MEMBER MUST BE IN GOOD STANDING AND ITS DUES AND ASSESSMENTS PAID IN FULL. |
| FORM 990, PART VI, SECTION B, LINE 11 | THE FINANCE COMMITTEE AND MANAGEMENT REVIEW AND APPROVE THE FORM 990. THE FORM IS THEN DISTRIBUTED TO ALL MEMBERS OF THE BOARD FOR THEIR REVIEW BEFORE FILING WITH THE INTERNAL REVENUE SERVICE. |
| FORM 990, PART VI, SECTION B, LINE 15A | THE TRANSCELERATE BOARD OF DIRECTORS PREPARES AND APPROVES THE COMPENSATION PACKAGE FOR THE CEO. |
| FORM 990, PART VI, SECTION C, LINE 19 | THE ORGANIZATION'S GOVERNING DOCUMENTS, FINANCIAL STATEMENTS, AND CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. |
| FORM 990, PART IX, LINE 11G | CONSULTANTS: PROGRAM SERVICE EXPENSES 3,502,901. MANAGEMENT AND GENERAL EXPENSES 1,148,756. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 4,651,657. OUTSIDE CONTRACT: PROGRAM SERVICE EXPENSES 9,192. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 9,192. |
| FORM 990,PART XII, QUESTION 2C | THE FINANCE COMMITTEE OF THE BOARD ASSUMES OVERSIGHT RESPONSIBILITY FOR THE AUDIT PROCESS. THIS PROCESS REMAINS UNCHANGED FROM THE PRIOR YEAR. |
| FORM 990,PART VI, SECTION B, LINE 13 | THE ORGANIZATION DOES NOT HAVE A WRITTEN WHISTLEBLOWER POLICY. A WHISTLEBLOWER POLICY IS BEING DEVELOPED AND WILL BE ADOPTED. |
| FORM 990,PART VI, SECTION B, LINE 14 | THE ORGANIZATION DOES NOT HAVE A WRITTEN DOCUMENT RETENTION AND DESTRUCTION POLICY. A DOCUMENT RETENTION AND DESTRUCTION POLICY IS BEING DEVELOPED AND WILL BE ADOPTED. |